Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center, discusses the use of PARP inhibitors and immunotherapy in gynecologic cancers.
Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center, discusses the use of PARP inhibitors and immunotherapy in gynecologic cancers.
Transcript
How have innovative new therapies changed the treatment landscape for gynecologic cancers?
I think that the new therapies that we now have approved, over the last 4 years in particular, have made a very valuable impact on patients. In particular, PARP inhibitors that are very effective in patients that have certain genomic mutations. Those patients are particularly patients with BRCA1 and 2 mutations, or patients that have certain genomic changes in the tumor that makes the tumor particularly sensitive to PARP inhibition. PARP inhibitors are oral drugs; we do like to give them after completion of chemotherapy for recurrent ovarian cancer, and we do now have several drugs approved.
We use this a fair amount in our clinical practice. These drugs are fairly new, so we still have to learn who the patients are that most benefit from these type of drugs, learn how to deal with the side effects, and how to use them most effectively. A lot of these drugs have not quite entered the first line treatment, but there are clinical trials going on that actually might show us that they are effective early on in the treatment process.
We’ve also used a fair amount of immunotherapy. Immunotherapy is a very young field, in particular gynecologic oncology, but in general we still need to understand who the patients are that benefit the most from immunotherapy. A number of immune checkpoint inhibitors have been approved for other solid tumors. We do need biomarkers to select those patients that can receive immunotherapy for gynecologic malignancies, but we do use immunotherapy, I would think quite a bit, in those patients that have no other treatment options. Immunotherapy is not without side effects, so I would say we need to be careful about what patients to treat, and again, who are the patients that benefit the most from these approaches.
.
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Overcoming Challenges to Value-Based Care Implementation: Grant Andres
November 10th 2023In an interview with The American Journal of Managed Care®, Grant Andres, BSc, DC, BSN, MSN-RN, senior director of clinical operations at Arizona Oncology, discussed the nuances of successfully implementing value-based care initiatives across a large organization.
Read More